TY - JOUR
T1 - Expression and role of the angiotensin II AT2 receptor in human prostate tissue
T2 - In search of a new therapeutic option for prostate cancer
AU - Guimond, Marie Odile
AU - Battista, Marie Claude
AU - Nikjouitavabi, Fatemeh
AU - Carmel, Maude
AU - Barres, Véronique
AU - Doueik, Alexandre A.
AU - Fazli, Ladan
AU - Gleave, Martin
AU - Sabbagh, Robert
AU - Gallo-Payet, Nicole
PY - 2013/7
Y1 - 2013/7
N2 - Background: Evidence shows that angiotensin II type 1 receptor (AT1R) blockers may be associated with improved outcome in prostate cancer patients. It has been proposed that part of this effect could be due to angiotensin II type 2 receptor (AT2R) activation, the only active angiotensin II receptor in this situation. This study aimed to characterize the localization and expression of AT2R in prostate tissues and to assess its role on cell morphology and number in prostatic epithelial cells in primary culture. Methods: AT2R and its AT2R-interacting protein (ATIP) expression were assessed on non-tumoral and tumoral human prostate using tissue microarray immunohistochemistry, binding assay, and Western blotting. AT2R effect on cell number was measured in primary cultures of epithelial cells from non-tumoral human prostate. Results: AT2R was localized at the level of the acinar epithelial layer and its expression decreased in cancers with a Gleason score 6 or higher. In contrast, ATIP expression increased with cancer progression. Treatment of primary cell cultures from non-tumoral prostate tissues with C21/M024, a selective AT2R agonist, alone or in co-incubation with losartan, an AT1R antagonist, significantly decreased cell number compared to untreated cells. Conclusions: AT2R and ATIP are present in non-tumoral human prostate tissues and differentially regulated according to Gleason score. The decrease in non-tumoral prostate cell number upon selective AT2R stimulation suggests that AT2R may have a protective role against prostate cancer development. Treatment with a selective AT2R agonist could represent a new approach for prostate cancer prevention or for patients on active surveillance.
AB - Background: Evidence shows that angiotensin II type 1 receptor (AT1R) blockers may be associated with improved outcome in prostate cancer patients. It has been proposed that part of this effect could be due to angiotensin II type 2 receptor (AT2R) activation, the only active angiotensin II receptor in this situation. This study aimed to characterize the localization and expression of AT2R in prostate tissues and to assess its role on cell morphology and number in prostatic epithelial cells in primary culture. Methods: AT2R and its AT2R-interacting protein (ATIP) expression were assessed on non-tumoral and tumoral human prostate using tissue microarray immunohistochemistry, binding assay, and Western blotting. AT2R effect on cell number was measured in primary cultures of epithelial cells from non-tumoral human prostate. Results: AT2R was localized at the level of the acinar epithelial layer and its expression decreased in cancers with a Gleason score 6 or higher. In contrast, ATIP expression increased with cancer progression. Treatment of primary cell cultures from non-tumoral prostate tissues with C21/M024, a selective AT2R agonist, alone or in co-incubation with losartan, an AT1R antagonist, significantly decreased cell number compared to untreated cells. Conclusions: AT2R and ATIP are present in non-tumoral human prostate tissues and differentially regulated according to Gleason score. The decrease in non-tumoral prostate cell number upon selective AT2R stimulation suggests that AT2R may have a protective role against prostate cancer development. Treatment with a selective AT2R agonist could represent a new approach for prostate cancer prevention or for patients on active surveillance.
KW - AT receptor
KW - angiotensin
KW - cancer
KW - human prostate
KW - primary cell culture
KW - proliferation
UR - http://www.scopus.com/inward/record.url?scp=84878471383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878471383&partnerID=8YFLogxK
U2 - 10.1002/pros.22653
DO - 10.1002/pros.22653
M3 - Article
C2 - 23389987
AN - SCOPUS:84878471383
SN - 0270-4137
VL - 73
SP - 1057
EP - 1068
JO - Prostate
JF - Prostate
IS - 10
ER -